Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: Lessons from mice, monkeys, and humans

Rejuvenation Research

Volumn 9, Issue 1, 2006, Pages 77-84

  Lemere, Cynthia A ^a,b   Maier, Marcel ^a   Jiang, Living ^a   Peng, Ying ^a   Seabrook, Timothy J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Center for Neurologic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; OLIGOMER; PERTUSSIS TOXIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY TITER; AUTOIMMUNITY; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DEMENTIA; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MICROGLIA; MONKEY; NONHUMAN; PHAGOCYTOSIS; PRIMATE; PRIORITY JOURNAL; SENILE PLAQUE; SYNAPSE; T LYMPHOCYTE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CERCOPITHECUS AETHIOPS; HUMANS; IMMUNIZATION; IMMUNIZATION, PASSIVE; MICE; MICE, TRANSGENIC;

MUS MUSCULUS; PRIMATES;

EID: 33646066257     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2006.9.77     Document Type: Conference Paper

References (60)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-766.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
3. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-339.
4. Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 1999;399: A23-A31.
5. Klein W. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 2002;41:345-352.
6. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004;41:213-228.
7. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44:181-193.
8. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
9. Lemere CA, Maron R, Spooner ET, et al. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann NY Acad Sci 2000;920:328-331.
10. Weiner HL, Lemere CA, Maron R, et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000;48:567-579.
11. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
12. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-985.
13. Das P, Murphy M, Younkin L, et al. Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001;22:721-727.
14. Sigurdsson EM, Scholtzova H, Mehta PD, et al. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001;159:439-447.
15. McLaurin J, Cecal R, Kierstead M, et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-1269.
16. Lemere CA, Spooner ET, LaFrancois J, et al. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis 2003;14:10-18.
17. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyl transferase activity. Infect Immunol 1995;63:1617-1623.
18. Lemere CA, Spooner ET, Leverone JF, et al. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 2002;23:991-1000.
19. Seabrook TJ, Iglesias M, Bloom JK, et al. Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 mice. Vaccine 2004;22:4075-4083.
20. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.
21. DeMattos R, Bales K, Cummins D, et al. Peripheral anti-Aβ antibody alters CNS and plasma clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
22. Dodart J-C, Bales K, Cannon K, et al. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-457.
23. Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss in a transgenic model of Alzheimer's disease. J Neurosci 2002;22:6331-6335.
24. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 2004;24:6144-6151.
25. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflam 2004;1:24.
26. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002;298:1379.
27. Racke MM, Boone LI, Hepburn DL, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci 2005;25:629-636.
28. Mohajeri MH, Saini K, Schultz JG, et al. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 2002;277:33012-33017.
29. Chauhan NB, Siegel GJ. Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. J Neurosci Res 2002;69:10-23.
30. Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 2003;74:142-147.
31. Bacskai BJ, Kajdasz ST, Christie RH, et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001;7:369-372.
32. Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-332.
33. Klyubin I, Walsh DM, Lemere CA, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005;11:556-561.
34. Gandy S, DeMattos RB, Lemere CA, et al. Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta). Alzheimer Dis Assoc Disord 2004;18:44-46.
35. Lemere CA, Beierschmitt A, Iglesias M, et al. Alzheimer's disease Abeta vaccine reduces central nervous system Abeta levels in a nonhuman primate, the Caribbean vervet. Am J Pathol 2004;165:283-297.
36. Solomon B, Koppel R, Hanan E, et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 1996;93:452-455.
37. Solomon B, Koppel R, Frenkel D, et al. Disaggregation of Alzheimer β-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109-4112.
38. Solomon B. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol 2001;20:697-703.
39. Das P, Howard V, Loosbrock N, et al. Amyloid-beta immunization effectively reduces amyloid deposition in FcR gamma -/- knock-out mice. J Neurosci 2003;23:8532-8538.
40. Bacskai B, Kajdasz S, McLellan M, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci 2002;22:7873-7878.
41. Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 2005;25:9096-9101.
42. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54.
43. Cribbs DH, Ghochikyan A, Vasilevko V, et al. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003;15:505-514.
44. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448-452.
45. Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20.
46. Masliah E, Hansen L, Adame A, et al. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129-131.
47. Furlan R, Brambilla E, Sanvito F, et al. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 2003;126:285-291.
48. Gilman S, Koller M, Black RS, et al. Clinical effects of A{beta} immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
49. Fox NC, Black RS, Gilman S, et al. Effects of A{beta} immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-1572.
50. Lee EB, Leng LZ, Lee VM, et al. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett 2005;579:2564-2568.
51. Lemere CA, Maron R, Selkoe DJ, et al. Nasal vaccination with β-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 2001;20:705-711.
52. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta-amyloid for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003;100:2023-2028.
53. Lee M, Bard F, Johnson-Wood K, et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Ann Neurol 2005;58:430-435.
54. Monsonego A, Zota V, Kami A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003;112:415-422.
55. Monsonego A, Maron R, Zota V, et al. Immune hyporesponsiveness to amyloid-β peptide in APP transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:10273-10278.
56. Leverone J, Spooner E, Lehmann H, et al. Aβ1-15 is less immunogenic than Aβ1-40/42 for intranasal immunization of wild-type mice but may be effective for boosting. Vaccine 2003;21:2197-2206.
57. Agadjanyan MG, Ghochikyan A, Petrushina I, et al. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 2005;174:1580-1586.
58. Sigurdsson EM, Knudsen E, Asuni A, et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci 2004;24:6277-6282.
59. Zurbriggen R, Amacker M, Kammer AR, et al. Virosome-based active immunization targets soluble amyloid species rather than plaques in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci 2005;27:157-166.
60. Maier M, Seabrook T, Lemere C. Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. Neurodegen Dis 2005;2:267-272.